SUPERIOR

CLINICALLY
MEANINGFUL

Ozempic® demonstrated superior weight loss vs Trulicity®2

*P<0.0001

THE WEIGHT LOSS

VS TRULICITY®†

Results apply to 1-mg dose of Ozempic® vs Trulicity® 1.5 mg.

Change from baseline in weight at Week 40

Mean baseline: 95.2 kg

–2.3 kg

–4.6 kg*

–3.0 kg

–6.5 kg*

Trulicity®

0.75 mg

Ozempic®

0.5 mg

Trulicity®

1.5 mg

Ozempic®

1 mg

n=299
n=301
n=299
n=300

VS JANUVIA®

VS INVOKANA®

ADA/EASD REPORT

SUPERIOR

CLINICALLY
MEANINGFUL

Ozempic®—more than twice as many patients experienced clinically
meaningful weight loss vs Trulicity®2

P<0.0001

Of patients treated with Ozempic® 1 mg...

EXPERIENCED

Compared with 8% of patients
 treated with Trulicity® 1.5 mg

EXPERIENCED

Compared with 30% of patients
 treated with Trulicity® 1.5 mg

x

Change from baseline in weight at Week 561

VS JANUVIA®1†

1.9 kg

4.3 kg*

6.1 kg*

Januvia®

100 mg

Ozempic®

0.5 mg

Ozempic®

1 mg

Mean baseline: 89.5 kg

n=407

n=409

n=409

*P<0.0001

ABSOLUTE HbA1c
ABSOLUTE WEIGHT LOSS
#presentationEngine [id$=weightReductionsAltPopup1EHTML] .content-wrapper{ position: absolute; top: 0; left: 0; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] [id$=popup1PassText]{ position: absolute; text-align: center; top: 435px; width: 281px; left: 587px; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] #popup1PassText span{ text-align: center; font-family: 'Frutiger LT Cond'; font-size: 14px; font-weight: 600; color: #fff; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] [id$=popup1ActText]{ position: absolute; text-align: center; font-size: 10px; top: 12px; width: 100%; left: -4px; letter-spacing: 0.5px; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] #popup1ActText span{ text-align: center; font-family: 'Frutiger LT Cond'; font-size: 14px; font-weight: 600; color: #fff; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .wrapper-for-text{ position: absolute; top: 0; left: 0; width: 100%; height: 100%; overflow: hidden; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] [id$=popup1ButtonBg]{ width: 260px; height: 60px; top: 419px; left: 585px; position: absolute; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .wrapper-for-filler{ position: absolute; top: 423px; left: 593px; width: 247px; height: 35px; border-radius: 15px; overflow: hidden; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .filler{ position: absolute; left: 0; width: 229px; height: 100%; border-radius: 15px; overflow: hidden; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .handler{ position: absolute; left: 794px; top: 423px; width: 48px; height: 51px; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .tabActive .move-left{ transform: translate(-196px ,0); } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .tabActive .move-right{ transform: translate(196px ,0); } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .move-left, #presentationEngine [id$=weightReductionsAltPopup1EHTML] .move-right{ transition: transform 0.5s linear; transform: translate(0, 0); } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .content-wrapper [id$=popup1HandlerReverse], #presentationEngine [id$=weightReductionsAltPopup1EHTML] .content-wrapper.tabActive [id$=popup1Handler]{ visibility: hidden; } #presentationEngine [id$=weightReductionsAltPopup1EHTML] .content-wrapper [id$=popup1Handler], #presentationEngine [id$=weightReductionsAltPopup1EHTML] .content-wrapper.tabActive [id$=popup1HandlerReverse]{ visibility: visible; }
setTimeout(() => { let clickCallback = function(){ document.querySelector('#presentationEngine [id$=weightReductionsAltPopup1EHTML] .content-wrapper').classList.toggle('tabActive'); }; const toggle1Selector = '#presentationEngine [id$=weightReductionsAltPopup1State1Toggler]'; const toggle2Selector = '#presentationEngine [id$=weightReductionsAltPopup1State2Toggler]'; var targets = [document.querySelector(toggle1Selector), document.querySelector(toggle2Selector)]; targets.forEach((target)=>{ target.onclick = clickCallback; }); }, 1000)

x

Change from baseline in weight at Week 5228

WEIGHT

LOSS

WITH OZEMPIC®1 MG

VS INVOKANA®1

4.2 kg*

5.3 kg*

Invokana®

300 mg

Ozempic®

1 mg

Mean baseline: 90.2 kg

n=394

n=394

*P=0.0029

ABSOLUTE HbA1c
ABSOLUTE WEIGHT LOSS
#presentationEngine [id$=weightReductionsAltPopup2EHTML] .content-wrapper{ position: absolute; top: 0; left: 0; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] [id$=popup2PassText]{ position: absolute; text-align: center; top: 435px; width: 281px; left: 587px; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] #popup2PassText span{ text-align: center; font-family: 'Frutiger LT Cond'; font-size: 14px; font-weight: 600; color: #fff; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] [id$=popup2ActText]{ position: absolute; text-align: center; font-size: 10px; top: 12px; width: 100%; left: -4px; letter-spacing: 0.5px; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] #popup2ActText span{ text-align: center; font-family: 'Frutiger LT Cond'; font-size: 14px; font-weight: 600; color: #fff; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .wrapper-for-text{ position: absolute; top: 0; left: 0; width: 100%; height: 100%; overflow: hidden; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] [id$=popup2ButtonBg]{ width: 260px; height: 60px; top: 419px; left: 585px; position: absolute; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .wrapper-for-filler{ position: absolute; top: 423px; left: 593px; width: 247px; height: 35px; border-radius: 15px; overflow: hidden; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .filler{ position: absolute; left: 0; width: 229px; height: 100%; border-radius: 15px; overflow: hidden; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .handler{ position: absolute; left: 794px; top: 423px; width: 48px; height: 51px; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .tabActive .move-left{ transform: translate(-196px ,0); } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .tabActive .move-right{ transform: translate(196px ,0); } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .move-left, #presentationEngine [id$=weightReductionsAltPopup2EHTML] .move-right{ transition: transform 0.5s linear; transform: translate(0, 0); } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .content-wrapper [id$=popup2HandlerReverse], #presentationEngine [id$=weightReductionsAltPopup2EHTML] .content-wrapper.tabActive [id$=popup2Handler]{ visibility: hidden; } #presentationEngine [id$=weightReductionsAltPopup2EHTML] .content-wrapper [id$=popup2Handler], #presentationEngine [id$=weightReductionsAltPopup2EHTML] .content-wrapper.tabActive [id$=popup2HandlerReverse]{ visibility: visible; }
setTimeout(() => { let clickCallback = function(){ document.querySelector('#presentationEngine [id$=weightReductionsAltPopup2EHTML] .content-wrapper').classList.toggle('tabActive'); }; const toggle1Selector = '#presentationEngine [id$=weightReductionsAltPopup2State1Toggler]'; const toggle2Selector = '#presentationEngine [id$=weightReductionsAltPopup2State2Toggler]'; var targets = [document.querySelector(toggle1Selector), document.querySelector(toggle2Selector)]; targets.forEach((target)=>{ target.onclick = clickCallback; }); }, 1000)

x

For adults with type 2 diabetes and a need to prioritise weight loss

THE 2019 UPDATE TO THE

2018 ADA/EASD CONSENSUS REPORT

RECOMMENDS A

GLP-1 RA

WITH GOOD EFFICACY

FOR WEIGHT LOSS6*

*Semaglutide

liraglutide

dulaglutide

exenatide

lixisenatide

ADA=American Diabetes Association; EASD=European Association for the Study of Diabetes; GLP-1 RA=glucagon-like peptide-1 receptor agonist.